文献速递痛风与晶体性关节病

多替诺雷对比非布司他治疗痛风的有效性与安全性:中国随机、多中心、双盲、3期试验

Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China.
PubMed 文献 · Arthritis Rheumatol · 2025-09-08

在中国痛风患者中开展的3期随机双盲多中心试验显示,多替诺雷4 mg/d在第24周实现血清尿酸≤6.0 mg/dL的应答率显著优于非布司他40 mg/d(73.6% vs 38.1%),多替诺雷2 mg/d在第12周不劣于非布司他40 mg/d,两组治疗中出现的不良事件发生率相似。

要点

  • 多替诺雷4 mg/d第24周应答率73.6%,非布司他40 mg/d为38.1%,调整差值35.9%(95%CI 27.4%-44.4%,P<0.0001)。
  • 多替诺雷2 mg/d第12周应答率55.5%,非布司他40 mg/d为50.5%,调整差值5.2%(95%CI -3.7%至14.2%),达到非劣效。
  • 多替诺雷组与非布司他组治疗中出现的不良事件发生率相似。

核心结论

  • 在中国痛风患者中,多替诺雷4 mg/d在第24周实现血清尿酸≤6.0 mg/dL方面优于非布司他40 mg/d,且耐受性良好。

研究设计与样本

  • 3期、多中心、随机、双盲、平行组研究,将符合条件的痛风患者按1:1随机分配接受口服多替诺雷或非布司他治疗。
  • 共随机451例患者,其中441例纳入全分析集(FAS)。
  • 主要终点为FAS第24周应答率(血清尿酸≤6.0 mg/dL的患者比例),用于证明多替诺雷4 mg/d对非布司他40 mg/d的优效性。
  • 次要终点包括第12周应答率,用于显示多替诺雷2 mg/d对非布司他40 mg/d的非劣效性,同时记录治疗中出现的不良事件(TEAEs)。

主要发现

  • 第24周应答率:多替诺雷4 mg/d组73.6% vs 非布司他40 mg/d组38.1%,调整差值35.9%(95%CI 27.4%-44.4%),P<0.0001。
  • 第12周应答率:多替诺雷2 mg/d组55.5% vs 非布司他40 mg/d组50.5%,调整差值5.2%(95%CI -3.7%至14.2%)。
  • 多替诺雷组与非布司他组治疗中出现的不良事件发生率相似。
  • 两组基线特征均衡。

关键数值与推荐

  • 主要终点应答率定义为血清尿酸水平≤6.0 mg/dL的患者比例,于第24周在全分析集(FAS)中评估。
  • 优效性检验:多替诺雷4 mg/d对比非布司他40 mg/d,第24周应答率73.6% vs 38.1%,调整差值35.9%(95%CI 27.4%-44.4%),P<0.0001。
  • 非劣效性检验:多替诺雷2 mg/d对比非布司他40 mg/d,第12周应答率55.5% vs 50.5%,调整差值5.2%(95%CI -3.7%至14.2%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Dotinurad is a selective urate reabsorption inhibitor that reduces serum urate levels. We compared the efficacy and safety of dotinurad with febuxostat in Chinese patients with gout. METHODS: This phase 3, multicenter, randomized, double-blind, parallel-group study randomly allocated (1:1) eligible patients with gout to receive oral dotinurad or febuxostat. The primary end point was the responder rate (proportion of patients achieving serum urate levels ≤6.0 mg/dL) at week 24 in the full analysis set (FAS) to demonstrate superiority of dotinurad 4 mg/day to febuxostat 40 mg/day. The secondary end points included the responder rate at week 12 to show the noninferiority of dotinurad 2 mg/day to febuxostat 40 mg/day. Treatment-emergent adverse events (TEAEs) were also recorded. RESULTS: A total of 451 patients were randomized, and 441 were included in the FAS. Baseline characteristics were well balanced between treatment groups. The responder rate at week 24 was significantly higher for dotinurad 4 mg/day versus febuxostat 40 mg/day (73.6% vs 38.1%; adjusted difference 35.9% [95% confidence interval (CI) 27.4%-44.4%]; P < 0.0001), and at week 12, dotinurad 2 mg/day was noninferior to febuxostat 40 mg/day (55.5% vs 50.5%; adjusted difference 5.2% [95% CI -3.7% to 14.2%]). Incidences of TEAEs in the dotinurad and febuxostat groups were similar. CONCLUSION: Dotinurad 4 mg/day was superior to febuxostat 40 mg/day in achieving serum urate levels ≤6.0 mg/dL at week 24 and was well tolerated in Chinese patients with gout.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Sun J, Wang Y, Cheng Y, et al. Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China. Arthritis Rheumatol. 2025. PMID: 40417858. doi:10.1002/art.43261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。